← All compounds · evidence tier first, by design
| Use | E1 | E2 | E3 | E4 | E5 | E6 | E7 | E8 |
|---|---|---|---|---|---|---|---|---|
| E1 Type 2 diabetes: glycaemic control and cardiovascular outcomes | E1 | |||||||
| E1 Chronic weight management (obesity or overweight) | E1 | |||||||
| E1 Early Alzheimer's disease (oral semaglutide) | E1 | |||||||
| E2 Heart failure with preserved ejection fraction and obesity | E2 | |||||||
| E2 Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis | E2 | |||||||
| E2 Knee osteoarthritis pain with obesity | E2 | |||||||
| E3 Alcohol use disorder (off-label, claimed) | E3 |
Semaglutide
Acylated analogue of human GLP-1 containing a non-coded amino acid (Aib) and a fatty diacid side chain attached via a linker; not representable as a plain one-letter sequence.
Non-standard residues or modifications: no plain one-letter sequence
Codes: NN9535 · Brands: Ozempic, Wegovy, Rybelsus, Kayshild · CAS 910463-68-2
A modified version of the gut hormone GLP-1, engineered to persist far longer in the body than the native hormone. It is an approved prescription medicine for type 2 diabetes (Ozempic, and Rybelsus as a tablet) and for chronic weight management (Wegovy), with later approvals in some jurisdictions for cardiovascular risk reduction (UK) and MASH (EU, as Kayshild). Falsified and unlicensed products have been reported by the UK MHRA. Status in China was not verified for this record.
- US A approved
- EU A approved
- UK A approved
- CA A approved
- AU A approved
- JP A approved
- CN ? not verified
01Regulatory status, by jurisdiction
| Jurisdiction | Status | Detail and primary source |
|---|---|---|
| US | Approved | Drugs@FDA NDA 209637 (Ozempic, Novo Nordisk), original approval 12/05/2017 as a new molecular entity. Wegovy is NDA 215256 (approved 06/04/2021); Rybelsus is NDA 213051 (approved 09/20/2019).“12/05/2017 ORIG-1 Approval Type 1 - New Molecular Entity STANDARD”Drugs@FDA: FDA-Approved Drugs, NDA 209637 · retrieved 2026-10-10 |
| EU | Approved | Centrally authorised as Ozempic (8 February 2018); also Rybelsus (2020), Wegovy (2022) and Kayshild (MASH, 2026), per the EMA medicines dataset.“The European Commission granted a marketing authorisation valid throughout the European Union for Ozempic on 8 February 2018.”Ozempic | European Medicines Agency (EPAR) · retrieved 2026-10-10 |
| UK | Approved | MHRA press release of 23 July 2024 approving a cardiovascular risk-reduction indication for Wegovy, which it states was already approved for obesity and weight management.“The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 July 2024, approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.”MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults · retrieved 2026-10-10 |
| CA | Approved | Health Canada Drug Product Database, Ozempic (drug code 96058), status Marketed since 2018-02-22. Wegovy and Rybelsus are also listed, as are subsequent-entry semaglutide products approved in 2026.“"drug_code":96058,"status":"Marketed","history_date":"2018-02-22","original_market_date":"2018-02-22"”Health Canada Drug Product Database API: status, drug code 96058 (Ozempic) · retrieved 2026-10-10 |
| AU | Approved | TGA Product Information repository lists PIs for Ozempic and Wegovy (semaglutide). The main TGA ARTG search (tga.gov.au) timed out on retrieval; the PI repository is a TGA database of registered products.“Search PI Trade Names and Active Ingredients containing semaglutide . 2 Documents available.”TGA eBS - Product and Consumer Medicine Information (search: semaglutide) · retrieved 2026-10-10 |
| JP | Approved | PMDA List of Approved Products (New Drugs, April 2004 to February 2026): Ozempic approved Mar. 23, 2018 as a new active ingredient for type 2 diabetes; Rybelsus approved Jun. 29, 2020; Wegovy approved Mar. 27, 2023 for obesity.“A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus.”PMDA List of Approved Products: New Drugs (April 2004 to February 2026) · retrieved 2026-10-10 |
| CN | Not yet verified from a primary source. No status is shown rather than an unsourced one. | |
Sport (WADA): Not prohibited. Not named on the Prohibited List. As an approved medicine it also falls outside class S0, which covers only substances without current regulatory approval: “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development” WADA source
02What the human evidence shows
Type 2 diabetes: glycaemic control and cardiovascular outcomes
n/c: not counted here; see the cited review.
Supported by a large phase 3 programme. In SUSTAIN-6 (3,297 people with type 2 diabetes at high cardiovascular risk), major adverse cardiovascular events occurred in 6.6% on semaglutide versus 8.9% on placebo (hazard ratio 0.74). In FLOW (3,533 people with type 2 diabetes and chronic kidney disease), the composite kidney and cardiovascular outcome was 24% lower with semaglutide (hazard ratio 0.76); the trial stopped early for efficacy.
- [1] Primary cardiovascular outcome in 6.6% vs 8.9% with placebo (HR 0.74) in people with type 2 diabetes
- [2] Composite kidney/cardiovascular outcome reduced (HR 0.76) in type 2 diabetes with chronic kidney disease
Registered-study counts: ClinicalTrials.gov intervention search “semaglutide AND type 2 diabetes”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Chronic weight management (obesity or overweight)
n/c: not counted here; see the cited review.
Multiple large placebo-controlled trials (the STEP programme). In STEP 1 (1,961 adults without diabetes), mean body-weight change at week 68 was -14.9% with semaglutide versus -2.4% with placebo. In SELECT (17,604 adults with overweight or obesity and established cardiovascular disease, no diabetes), major cardiovascular events occurred in 6.5% versus 8.0% (hazard ratio 0.80). Discontinuation for adverse events was about twice as common with semaglutide (16.6% vs 8.2%).
- [3] Mean weight change -14.9% vs -2.4% with placebo at week 68 in adults with overweight or obesity
- [4] Major adverse cardiovascular events 6.5% vs 8.0% (HR 0.80) in adults with cardiovascular disease and overweight/obesity
Registered-study counts: ClinicalTrials.gov intervention search “semaglutide AND obesity”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Early Alzheimer's disease (oral semaglutide)
n/c: not counted here; see the cited review.
Two adequately powered phase 3 trials (evoke and evoke+, 3,808 participants in total) found no slowing of clinical progression: change in CDR-SB at week 104 did not differ from placebo in either trial. The tier reflects the strength of the evidence, which consistently shows no benefit.
- [5] Commentary on evoke/evoke+, in which semaglutide did not slow CDR-SB progression versus placebo in early Alzheimer's disease
Registered-study counts: ClinicalTrials.gov intervention search “semaglutide AND Alzheimer”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Heart failure with preserved ejection fraction and obesity
n/c: not counted here; see the cited review.
In STEP-HFpEF (529 adults with HFpEF and obesity), the heart-failure symptom score (KCCQ-CSS) improved by 16.6 points with semaglutide versus 8.7 with placebo, and body weight fell 13.3% versus 2.6%. The trial measured symptoms and function; it was not powered for heart-failure hospitalisation or death.
- [6] KCCQ-CSS change 16.6 vs 8.7 points with placebo in HFpEF with obesity
Registered-study counts: ClinicalTrials.gov intervention search “semaglutide AND heart failure”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis
n/c: not counted here; see the cited review.
In the first part of the phase 3 ESSENCE trial (800 patients with biopsy data), resolution of steatohepatitis without worsening fibrosis occurred in 62.9% with semaglutide versus 34.3% with placebo, and fibrosis improvement in 36.8% versus 22.4%. These are histological surrogate endpoints; the clinical-outcomes part of ESSENCE is still under way (ClinicalTrials.gov status: active, not recruiting).
- [7] MASH resolution 62.9% vs 34.3%; fibrosis improvement 36.8% vs 22.4% with placebo
Registered-study counts: ClinicalTrials.gov intervention search “semaglutide AND steatohepatitis”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Knee osteoarthritis pain with obesity
n/c: not counted here; see the cited review.
One phase 3 trial (STEP 9, 407 participants with obesity and knee osteoarthritis): WOMAC pain score fell 41.7 points with semaglutide versus 27.5 with placebo at week 68, alongside 13.7% versus 3.2% weight loss. The trial cannot separate a direct joint effect from the effect of weight loss.
- [8] WOMAC pain change -41.7 vs -27.5 points with placebo at week 68
Registered-study counts: ClinicalTrials.gov intervention search “semaglutide AND osteoarthritis”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Alcohol use disorder (off-label, claimed)
n/c: not counted here; see the cited review.
One small randomised trial (48 participants, 9 weeks) found less alcohol consumed in a laboratory self-administration task and fewer drinks per drinking day, but no change in drinks per calendar day or number of drinking days. No adequately powered trial has reported.
- [9] Reduced laboratory alcohol self-administration and drinks per drinking day; no change in drinking days (n=48)
Registered-study counts: ClinicalTrials.gov intervention search “semaglutide AND alcohol”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Key registered trials
| NCT | Title (as registered) | Phase | Status |
|---|---|---|---|
| NCT01720446 | Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | 3 | Completed |
| NCT03548935 | STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | 3 | Completed |
| NCT03574597 | Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | 3 | Completed |
| NCT03819153 | A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | 3 | Completed |
| NCT04788511 | Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity | 3 | Completed |
| NCT04822181 | Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | 3 | Active, not recruiting |
| NCT04777396 | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | 3 | Completed |
| NCT04777409 | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | 3 | Completed |
03Safety signals
- Gastrointestinal adverse events, including pancreatitis, bowel obstruction and gastroparesis [10]
Nausea, vomiting and diarrhoea are the most common adverse events in all trials. A US claims-database cohort found higher risk of pancreatitis, bowel obstruction and gastroparesis (not biliary disease) with GLP-1 receptor agonists used for weight loss than with bupropion-naltrexone; confidence intervals were wide. The UK MHRA strengthened pancreatitis warnings for the class in January 2026. - Gallbladder and biliary disease [11]
Meta-analysis of 76 randomised trials (103,371 patients): GLP-1 receptor agonist use associated with increased risk of gallbladder or biliary disease (RR 1.37), higher in weight-loss trials (RR 2.29) and at higher doses. - Non-arteritic anterior ischaemic optic neuropathy (NAION) [12]
Retrospective matched cohort of neuro-ophthalmology patients at one academic institution reported higher NAION risk with semaglutide (HR 4.28 in type 2 diabetes). The MHRA issued a Drug Safety Update on NAION risk for Wegovy, Ozempic and Rybelsus (February 2026). - Diabetic retinopathy complications in type 2 diabetes [1]
In SUSTAIN-6, retinopathy complications (vitreous haemorrhage, blindness, or conditions requiring treatment) were more frequent with semaglutide than placebo. - Thyroid C-cell tumours in rodents [13]
GLP-1 receptor agonists activate thyroid C-cells and cause C-cell proliferation in rodents; relevance to humans is not established.
04What is unknown
- Long-term effects beyond roughly four years of continuous exposure; the longest outcome trial (SELECT) had mean follow-up of about 40 months
- Whether the NAION association reported in observational data is causal, and its absolute risk in the general treated population
- Human relevance of the thyroid C-cell tumours seen in rodents; no adequately sized long-term human study has resolved it
- Effects of discontinuation on weight and cardiometabolic outcomes over years after stopping
- Identity, purity and content of compounded and unlicensed semaglutide products, which have not been systematically assayed in the published literature
05Product quality
No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.
06Citations
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016). doi:10.1056/NEJMoa1607141
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (2024). doi:10.1056/NEJMoa2403347
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021). doi:10.1056/NEJMoa2032183
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023). doi:10.1056/NEJMoa2307563
- Semaglutide for Alzheimer's disease after evoke and evoke+ (2026). doi:10.1016/s0140-6736(26)00514-3
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (2023). doi:10.1056/NEJMoa2306963
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (2025). doi:10.1056/NEJMoa2413258
- Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (2024). doi:10.1056/NEJMoa2403664
- Once-Weekly Semaglutide in Adults With Alcohol Use Disorder (2025). doi:10.1001/jamapsychiatry.2024.4789
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. doi:10.1001/jama.2023.19574
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. doi:10.1001/jamainternmed.2022.0338
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. doi:10.1001/jamaophthalmol.2024.2296
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation. doi:10.1210/en.2009-1272
Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.
07Mechanism
Semaglutide is a GLP-1 receptor agonist. Its fatty-acid side chain binds albumin, which slows clearance and prolongs its duration of action.
Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.
Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.